2008;46:584 593. doi: 10.1086/525536. 167. Steed ME, Vidaillac C, Rybak MJ. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2010;54:5187 5192. doi: 10.1128/ AAC.00536-10. 168. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. Use of antistaphylococcal beta-lactams to increase dapto- mycin activity in eradicating persistent bacteremia due to methicillin- resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158 163. doi: 10.1093/cid/cir340. 169. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. -Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56:6192 6200. doi: 10.1128/AAC.01525-12. 170. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-interme- diate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model [published correction appears in Antimicrob Agents Chemother. 2013;57:1565]. Antimicrob Agents Chemother. 2013;57:66 73. doi: 10.1128/AAC.01586-12. 171. Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, Pogliano J, Rybak MJ. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin- intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother. 2013;57:2376 2379. doi: 10.1128/ AAC.02354-12. 172. Jang HC, Kim SH, Kim KH, Kim CJ, Lee S, Song KH, Jeon JH, Park WB, Kim HB, Park SW, Kim NJ, Kim EC, Oh MD, Choe KW. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bac- teremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis. 2009;49:395 401. doi: 10.1086/600295. 173. Tattevin P, Uhel F, Fily F. Observational studies of salvage treatment for persistent bacteremia: beware of survivor treatment selection bias. Clin Infect Dis. 2009;49:1960; author reply 1961. doi: 10.1086/648500. 